GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protara Therapeutics Inc (NAS:TARA) » Definitions » Operating Margin %

Protara Therapeutics (Protara Therapeutics) Operating Margin % : 0.00% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Protara Therapeutics Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Protara Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-11.85 Mil. Protara Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Protara Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Protara Therapeutics's Operating Margin % or its related term are showing as below:


TARA's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -155.555
* Ranked among companies with meaningful Operating Margin % only.

Protara Therapeutics's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Protara Therapeutics's Operating Income for the three months ended in Mar. 2024 was $-11.85 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2024 was $-45.73 Mil.


Protara Therapeutics Operating Margin % Historical Data

The historical data trend for Protara Therapeutics's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protara Therapeutics Operating Margin % Chart

Protara Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Margin %
Get a 7-Day Free Trial - - - - -

Protara Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Protara Therapeutics's Operating Margin %

For the Biotechnology subindustry, Protara Therapeutics's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Protara Therapeutics's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Protara Therapeutics's Operating Margin % falls into.



Protara Therapeutics Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Protara Therapeutics's Operating Margin % for the fiscal year that ended in Dec. 2023 is calculated as

Operating Margin %=Operating Income (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=-43.613 / 0
= %

Protara Therapeutics's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=-11.851 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Protara Therapeutics  (NAS:TARA) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Protara Therapeutics Operating Margin % Related Terms

Thank you for viewing the detailed overview of Protara Therapeutics's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Protara Therapeutics (Protara Therapeutics) Business Description

Traded in Other Exchanges
Address
345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
Executives
Patrick Fabbio officer: Chief Financial Officer 2 PITNEY COURT, BASKING RIDGE NJ 07920
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Jesse Shefferman director, officer: CEO and President C/O ARTARA THERAPEUTICS,INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Hannah Fry officer: VP, Controller 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Jathin Bandari officer: Chief Medical Officer C/O PROTORA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Jane Huang director C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Martin Sebastian Olivo officer: Chief Medical Officer C/O PROTARA THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 3RD FLOOR, NEW YORK NY 10010
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Blaine Davis officer: Chief Financial Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Randall Marshall 10 percent owner C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Barry P Flannelly director ROUTE 141 AND HENRY CLAY ROAD, WILMINGTON DE 19880
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julio Casoy officer: Chief Medical Officer C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014
Jacqueline Zummo officer: Sr. Vice President, Research C/O ARTARA THERAPEUTICS, INC., 1 LITTLE WEST 12TH STREET, NEW YORK NY 10014

Protara Therapeutics (Protara Therapeutics) Headlines

From GuruFocus

Protara Therapeutics Announces Departure of Chief Financial Officer

By GuruFocusNews GuruFocusNews 07-01-2022

Protara Therapeutics Announces Departure of Chief Financial Officer

By GuruFocusNews GuruFocusNews 06-21-2022